Lexeo Therapeutics, Inc. (LXEO), Tuesday announced a partnership with Perceptive Xontogeny Venture Funds and venBio Partners to develop therapies for genetic cardiac diseases utilizing a novel non-viral RNA platform.
The investment, totaling upto $40 million, will help to launch a new entity, which will entirely focus on advancing research for novel RNA-based therapeutics via non-viral delivery for the treatment of genetically mediated cardiac conditions.
Under the deal, the New York City-based company will share its expertise in developing cardiac genetic medicines, certain existing preclinical intellectual property, and technology, which will be integrated with a novel non-viral delivery platform.
Notably, the funding for the new entity will be non-dilutive to existing Lexeo shareholders.
In the pre-market hours, LXEO is trading at $4.1, up 3.54 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.